Denali Therapeutics Inc.

DNLI Nasdaq SEC CIK 1714899
Follow Denali Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $17.8M
Net income $70.1M +155.3% vs same quarter last year
EPS, diluted $0.37 +150% vs same quarter last year
Operating cash flow −$117.4M −9.5% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$3.6M
$17.8M
Q4 24 Q2 25 Q3 25 Q4 25 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$750M−$500M−$250M$0$250M$500MFY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$512.5M
FY24$0−$422.8M
FY23$330.5M−$145.2M
FY22$105.1M−$326M
FY21$48.7M−$290.6M
FY20$335.6M$71.1M
FY19$26.3M−$197.6M
FY18$129.1M−$36.2M
FY17$0−$88.2M
FY16$0−$86.7M
FY15--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1000%−750%−500%−250%0%250%FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23−59.5%−43.9%
FY22−324.3%−310.3%
FY21−607.8%−597.2%
FY2018.7%21.2%
FY19−810%−750.8%
FY18−35.9%−28.1%
FY17--
FY16--
FY15--
Free cash flowOperating cash flow minus capital expenditure
−$500M−$250M$0$250M$500MFY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$422.1M
FY24−$363.6M
FY23−$370.9M
FY22−$262.5M
FY21−$219.9M
FY20$413.1M
FY19−$169.5M
FY18$46.7M
FY17−$79.5M
FY16−$78M
FY15-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Denali Therapeutics
  • Healthcare median
−800%−600%−400%−200%0%200%FY15FY17FY19FY21FY23FY25
Show the numbers
YearDenali TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23−43.9%−58%
FY22−310.3%−80.4%
FY21−597.2%−71.8%
FY2021.2%−62.2%
FY19−750.8%−46.2%
FY18−28.1%−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%